<bill session="115" type="s" number="1049" updated="2019-04-18T16:35:47Z">
  <state datetime="2017-05-04">REFERRED</state>
  <status>
    <introduced datetime="2017-05-04"/>
  </status>
  <introduced datetime="2017-05-04"/>
  <titles>
    <title type="official" as="introduced">A bill to allow the Secretary of Health and Human Services to require that risk evaluation and mitigation strategies for certain drugs include communication plans that provide information about drug formulations or properties described in the drug labeling.</title>
    <title type="short" as="introduced">Opioid Addiction Risk Transparency Act</title>
    <title type="short" as="introduced">Opioid Addiction Risk Transparency Act</title>
    <title type="display">Opioid Addiction Risk Transparency Act</title>
  </titles>
  <sponsor bioguide_id="H001076"/>
  <cosponsors>
    <cosponsor bioguide_id="Y000064" joined="2017-05-04"/>
  </cosponsors>
  <actions>
    <action datetime="2017-05-04">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2017-05-04" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSHR" name="Senate Health, Education, Labor, and Pensions" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="115" relation="unknown" number="934"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Health personnel"/>
  </subjects>
  <amendments/>
  <summary date="2017-05-04T04:00:00Z" status="Introduced in Senate">Opioid Addiction Risk Transparency Act

This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require a communication plan that is part of a medication's risk evaluation and mitigation strategy to include informing health care providers about the meaning of terms related to properties of the medication described in the labeling.</summary>
  <committee-reports/>
</bill>
